Danaher's diversified global operations leverage an expanding scope of digital technologies and software to coordinate its assets, internal processes and interfirm relationships, as evidenced by its range of products, software and services across segments and significant investments to globalize its manufacturing, research and development and customer-facing resources. Rapid technological development, particularly in computing, automation, artificial intelligence, mobile connectivity, communications and digitization, underpins the life sciences segment’s instruments, consumables and software that support the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs and automation products for genomic sample preparation; the diagnostics segment’s analytical instruments, reagents, consumables, software and services for molecular diagnostics, acute care and pathology; and the environmental & applied solutions and product identification businesses’ instrumentation, consumables, software, services and disinfection systems including color and appearance management, packaging design and quality management, marking, coding and traceability applications. The acquisition of Cytiva has expanded the company’s technology portfolio with new product and service offerings that complement biologics workflow solutions, reinforcing IT resources and management skills to drive productivity improvement initiatives and new product development, sales, service and marketing growth investments. These capabilities enable the mobilization and deployment of technology-based resources in combination with other strategic resources to support demand for COVID-19-related testing, treatment and vaccine development, enhance operational efficiency, provide connectivity and market responsiveness, and transform Danaher into a competitive force through continuous integration of IT infrastructure, data and information management and organizational processes.